# Vertex Pharmaceuticals Inc / Ma: financial statements, quarterly

VRTX · Nasdaq · CIK 875320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vrtx.md) · [Financials](/companies/vrtx/financials.md) · [Filings](/companies/vrtx/filings.md) · [Insiders](/companies/vrtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vrtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,484](/filings/0000875320-24-000223.md) | [2,518 d](/filings/0000875320-26-000056.md) | [2,691](/filings/0000875320-25-000192.md) | [2,646](/filings/0000875320-25-000216.md) | [2,772](/filings/0000875320-25-000232.md) | [2,912 d](/filings/0000875320-26-000056.md) | [2,770](/filings/0000875320-26-000173.md) | [2,965](/filings/0000875320-26-000259.md) | [3,076](/filings/0000875320-25-000232.md) | [3,190 d](/filings/0000875320-26-000056.md) | [2,987](/filings/0000875320-26-000173.md) | [3,334](/filings/0000875320-26-000259.md) |
| Cost of revenue | $m | [319](/filings/0000875320-24-000223.md) | [368 d](/filings/0000875320-26-000056.md) | [343](/filings/0000875320-25-000192.md) | [372](/filings/0000875320-25-000216.md) | [393](/filings/0000875320-25-000232.md) | [423 d](/filings/0000875320-26-000056.md) | [363](/filings/0000875320-26-000173.md) | [408](/filings/0000875320-26-000259.md) | [415](/filings/0000875320-25-000232.md) | [466 d](/filings/0000875320-26-000056.md) | [393](/filings/0000875320-26-000173.md) | [489](/filings/0000875320-26-000259.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [264](/filings/0000875320-24-000223.md) | [369 d](/filings/0000875320-26-000056.md) | [343](/filings/0000875320-25-000192.md) | [372](/filings/0000875320-25-000216.md) | [372](/filings/0000875320-25-000232.md) | [378 d](/filings/0000875320-26-000056.md) | [396](/filings/0000875320-26-000173.md) | [425](/filings/0000875320-26-000259.md) | [445](/filings/0000875320-25-000232.md) | [487 d](/filings/0000875320-26-000056.md) | [494](/filings/0000875320-26-000173.md) | [582](/filings/0000875320-26-000259.md) |
| Operating income | $m | [1,038](/filings/0000875320-24-000223.md) | [989 d](/filings/0000875320-26-000056.md) | [1,140](/filings/0000875320-25-000192.md) | [(3,515)](/filings/0000875320-25-000216.md) | [1,116](/filings/0000875320-25-000232.md) | [1,026 d](/filings/0000875320-26-000056.md) | [630](/filings/0000875320-26-000173.md) | [1,151](/filings/0000875320-26-000259.md) | [1,186](/filings/0000875320-25-000232.md) | [1,206 d](/filings/0000875320-26-000056.md) | [1,138](/filings/0000875320-26-000173.md) | [1,247](/filings/0000875320-26-000259.md) |
| Interest expense | $m | [10.9](/filings/0000875320-24-000223.md) | [10.6 d](/filings/0000875320-26-000056.md) | [10.4](/filings/0000875320-25-000192.md) | [9.9](/filings/0000875320-25-000216.md) | [7.5](/filings/0000875320-25-000232.md) | [2.8 d](/filings/0000875320-26-000056.md) | [3.0](/filings/0000875320-25-000192.md) | [3.7](/filings/0000875320-25-000216.md) | [3.3](/filings/0000875320-25-000232.md) | [3.3 d](/filings/0000875320-26-000056.md) | not reported | not reported |
| Income tax | $m | [144](/filings/0000875320-24-000223.md) | [179 d](/filings/0000875320-26-000056.md) | [180](/filings/0000875320-25-000192.md) | [202](/filings/0000875320-25-000216.md) | [179](/filings/0000875320-25-000232.md) | [224 d](/filings/0000875320-26-000056.md) | [84.1](/filings/0000875320-26-000173.md) | [250](/filings/0000875320-26-000259.md) | [216](/filings/0000875320-25-000232.md) | [140 d](/filings/0000875320-26-000056.md) | [222](/filings/0000875320-26-000173.md) | [292](/filings/0000875320-26-000259.md) |
| Net income | $m | [1,035](/filings/0000875320-24-000223.md) | [969 d](/filings/0000875320-26-000056.md) | [1,100](/filings/0000875320-25-000192.md) | [(3,594)](/filings/0000875320-25-000216.md) | [1,045](/filings/0000875320-25-000232.md) | [913 d](/filings/0000875320-26-000056.md) | [646](/filings/0000875320-26-000173.md) | [1,033](/filings/0000875320-26-000259.md) | [1,083](/filings/0000875320-25-000232.md) | [1,191 d](/filings/0000875320-26-000056.md) | [1,031](/filings/0000875320-26-000173.md) | [1,100](/filings/0000875320-26-000259.md) |
| Diluted EPS | $ per share | [3.97](/filings/0000875320-24-000223.md) | not reported | [4.21](/filings/0000875320-25-000192.md) | [(13.92)](/filings/0000875320-25-000216.md) | [4.01](/filings/0000875320-25-000232.md) | not reported | [2.49](/filings/0000875320-26-000173.md) | [3.99](/filings/0000875320-26-000259.md) | [4.20](/filings/0000875320-25-000232.md) | not reported | [4.02](/filings/0000875320-26-000173.md) | [4.31](/filings/0000875320-26-000259.md) |
| Basic EPS | $ per share | [4.01](/filings/0000875320-24-000223.md) | not reported | [4.26](/filings/0000875320-25-000192.md) | [(13.92)](/filings/0000875320-25-000216.md) | [4.05](/filings/0000875320-25-000232.md) | not reported | [2.52](/filings/0000875320-26-000173.md) | [4.02](/filings/0000875320-26-000259.md) | [4.24](/filings/0000875320-25-000232.md) | not reported | [4.06](/filings/0000875320-26-000173.md) | [4.34](/filings/0000875320-26-000259.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [11.1](/filings/0000875320-24-000223.md) | [10.4](/filings/0000875320-26-000056.md) | [9.2](/filings/0000875320-25-000192.md) | [4.6](/filings/0000875320-25-000216.md) | [5.2](/filings/0000875320-25-000232.md) | [4.6](/filings/0000875320-26-000259.md) | [4.7](/filings/0000875320-26-000173.md) | [5.0](/filings/0000875320-26-000259.md) | [4.9](/filings/0000875320-25-000232.md) | [5.1](/filings/0000875320-26-000259.md) | [5.5](/filings/0000875320-26-000173.md) | [6.1](/filings/0000875320-26-000259.md) |
| Current assets | $bn | [14.7](/filings/0000875320-23-000031.md) | [14.1](/filings/0000875320-25-000053.md) | [13.3](/filings/0000875320-24-000139.md) | [8.9](/filings/0000875320-24-000198.md) | [9.8](/filings/0000875320-24-000223.md) | [9.6](/filings/0000875320-26-000056.md) | [10.0](/filings/0000875320-25-000192.md) | [10.4](/filings/0000875320-25-000216.md) | [10.6](/filings/0000875320-25-000232.md) | [11.2](/filings/0000875320-26-000259.md) | [11.7](/filings/0000875320-26-000173.md) | [12.5](/filings/0000875320-26-000259.md) |
| Total assets | $bn | [21.7](/filings/0000875320-23-000031.md) | [22.7](/filings/0000875320-25-000053.md) | [23.9](/filings/0000875320-24-000139.md) | [20.1](/filings/0000875320-24-000198.md) | [22.2](/filings/0000875320-24-000223.md) | [22.5](/filings/0000875320-26-000056.md) | [22.9](/filings/0000875320-25-000192.md) | [24.0](/filings/0000875320-25-000216.md) | [24.9](/filings/0000875320-25-000232.md) | [25.6](/filings/0000875320-26-000259.md) | [26.5](/filings/0000875320-26-000173.md) | [27.4](/filings/0000875320-26-000259.md) |
| Current liabilities | $bn | [3.6](/filings/0000875320-23-000031.md) | [3.5](/filings/0000875320-25-000053.md) | [3.8](/filings/0000875320-24-000139.md) | [3.5](/filings/0000875320-24-000198.md) | [4.0](/filings/0000875320-24-000223.md) | [3.6](/filings/0000875320-26-000056.md) | [3.8](/filings/0000875320-25-000192.md) | [4.1](/filings/0000875320-25-000216.md) | [4.5](/filings/0000875320-25-000232.md) | [3.9](/filings/0000875320-26-000259.md) | [3.9](/filings/0000875320-26-000173.md) | [3.9](/filings/0000875320-26-000259.md) |
| Total liabilities | $bn | [5.2](/filings/0000875320-23-000031.md) | [5.1](/filings/0000875320-25-000053.md) | [5.4](/filings/0000875320-24-000139.md) | [5.4](/filings/0000875320-24-000198.md) | [6.6](/filings/0000875320-24-000223.md) | [6.1](/filings/0000875320-26-000056.md) | [6.4](/filings/0000875320-25-000192.md) | [6.9](/filings/0000875320-25-000216.md) | [7.5](/filings/0000875320-25-000232.md) | [7.0](/filings/0000875320-26-000259.md) | [7.1](/filings/0000875320-26-000173.md) | [7.2](/filings/0000875320-26-000259.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [16.5](/filings/0000875320-24-000223.md) | [17.6](/filings/0000875320-26-000056.md) | [18.5](/filings/0000875320-25-000216.md) | [14.8](/filings/0000875320-25-000232.md) | [15.6](/filings/0000875320-25-000232.md) | [16.4](/filings/0000875320-26-000259.md) | [16.5](/filings/0000875320-26-000259.md) | [17.2](/filings/0000875320-26-000259.md) | [17.3](/filings/0000875320-25-000232.md) | [18.7](/filings/0000875320-26-000259.md) | [19.4](/filings/0000875320-26-000259.md) | [20.2](/filings/0000875320-26-000259.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,268 d](/filings/0000875320-24-000223.md) | [235 d](/filings/0000875320-26-000056.md) | [1,307](/filings/0000875320-25-000192.md) | [(3,754) d](/filings/0000875320-25-000216.md) | [1,370 d](/filings/0000875320-25-000232.md) | [585 d](/filings/0000875320-26-000056.md) | [819](/filings/0000875320-26-000173.md) | [1,073 d](/filings/0000875320-26-000259.md) | [1,241 d](/filings/0000875320-25-000232.md) | [498 d](/filings/0000875320-26-000056.md) | [1,428](/filings/0000875320-26-000173.md) | [1,125 d](/filings/0000875320-26-000259.md) |
| Capital expenditure | $m | [40.6 d](/filings/0000875320-24-000223.md) | [58.1 d](/filings/0000875320-26-000056.md) | [68.4](/filings/0000875320-25-000192.md) | [69.0 d](/filings/0000875320-25-000216.md) | [67.7 d](/filings/0000875320-25-000232.md) | [92.6 d](/filings/0000875320-26-000056.md) | [40.7](/filings/0000875320-26-000173.md) | [146 d](/filings/0000875320-26-000259.md) | [102 d](/filings/0000875320-25-000232.md) | [149 d](/filings/0000875320-26-000056.md) | [133](/filings/0000875320-26-000173.md) | [112 d](/filings/0000875320-26-000259.md) |
| Share repurchases | $m | [117 d](/filings/0000875320-24-000223.md) | [150 d](/filings/0000875320-26-000056.md) | [131](/filings/0000875320-25-000192.md) | [320 d](/filings/0000875320-25-000216.md) | [308 d](/filings/0000875320-25-000232.md) | [418 d](/filings/0000875320-26-000056.md) | [426](/filings/0000875320-26-000173.md) | [392 d](/filings/0000875320-26-000259.md) | [1,071 d](/filings/0000875320-25-000232.md) | [128 d](/filings/0000875320-26-000056.md) | [337](/filings/0000875320-26-000173.md) | [470 d](/filings/0000875320-26-000259.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [260](/filings/0000875320-23-000031.md) | [260](/filings/0000875320-24-000139.md) | [260](/filings/0000875320-24-000198.md) | [261](/filings/0000875320-24-000223.md) | [261](/filings/0000875320-25-000192.md) | [258](/filings/0000875320-25-000216.md) | [261](/filings/0000875320-25-000232.md) | [260](/filings/0000875320-26-000173.md) | [259](/filings/0000875320-26-000259.md) | [258](/filings/0000875320-25-000232.md) | [256](/filings/0000875320-26-000173.md) | [255](/filings/0000875320-26-000259.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 253,460,924 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0000875320-26-000259.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.